Canaccord Genuity maintains Aclaris Therapeutics at Buy, raises price target to $13 from $10

Canaccord Genuity reaffirmed its Buy rating for Aclaris Therapeutics and increased its price target to $13 from $10, representing a 30% increase. This target suggests a 227.5% upside from the Oct 30 closing price of $3.97.

Original reporting
Published Oct 31, 2026, 12:26 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 31, 2026, 12:33 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Canaccord Genuity maintains Aclaris Therapeutics at Buy, raises price target to $13 from $10 — source image
Decision brief

The 30-second read

$ACRSBullishLow
01

Why it matters

Analyst price‑target upgrades can move thinly‑traded stocks, but the effect is often short‑lived without substantive catalyst.

02

Market read

A modest analyst upgrade with a higher price target may generate modest buying interest.

03

What to watch

No new clinical data or regulatory events accompany the upgrade.

Relevance 5/10Novelty 5/10Timing: today

Background

Aclaris Therapeutics is a small-cap biotech listed on NASDAQ.

Company-level read

Ticker impact

$ACRSBullishMedium confidence
Context

Canaccord Genuity raised its price target on Aclaris Therapeutics to $13 from $10.

Expected impact

potential upward pressure as the market prices in the higher target

Evidence & confidence

The new target implies a 227% upside from the recent close, which could prompt short-covering and buying.

Market effects

May boost sentiment in the biotech sector.

Limited to US biotech investors.

Minimal global impact.

Counterpoint

The target raise could be overly optimistic given the company's cash burn.

Key entities

  • Canaccord Genuity

    Equity research firm that issued the rating.

  • Aclaris Therapeutics

    Biopharmaceutical company focused on dermatology and oncology.

Related articles

$ACRSMedAI 8/10

Wedbush cuts Aclaris Therapeutics stock rating on trial miss

Wedbush downgraded Aclaris Therapeutics (ACRS) to Neutral, cutting its price target to $3.00 from $8.00 after a Phase 2 trial failure. The stock is down 13% over the past week. Wedbush expects Aclaris to shift focus to eosinophilic esophagitis but notes growing competition. Other analysts have mixed views on ACRS's pipeline and potential.

$CGONMed

Biotech's Monday Split: Two Trial Wins, One Trial Miss and an FDA Rejection

Biotech stocks moved amid clinical and regulatory news. CG Oncology's bladder cancer drug met its primary endpoint, reducing recurrence risk by 68%. Lexeo's gene therapy showed promising interim data. Summit Therapeutics' lung cancer drug received an FDA rejection, and Aclaris' atopic dermatitis treatment missed Phase 2 goals. The S&P 500 and Nasdaq fell 1.92% and 2.49%, respectively, according to CNBC.

$ACRSHighAI 8/10

Aclaris stock falls after atopic dermatitis trial fails

Aclaris Therapeutics (NASDAQ:ACRS) shares dropped 6% after its Phase 2 ADMIRATION trial for atopic dermatitis treatment failed to meet primary and secondary endpoints. The trial evaluated bosakitug (ATI-045), which showed target engagement but did not improve Eczema Area and Severity Index scores. The company remains focused on other treatments, including modzatinib (ATI-2138) for lichen planus, with a Phase 2b trial underway.

$ACRSHighAI 8/10

Aclaris Therapeutics’ mAb fails in Phase II eczema trial

Aclaris Therapeutics' Phase II trial of bosakitug for atopic dermatitis failed to meet primary and secondary endpoints, though the drug showed target engagement. The company remains focused on other treatments, including modzatinib and ATI-052. The atopic dermatitis market is projected to grow to $21.5bn by 2033, with key players like Sanofi and AbbVie.